专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

AU3071392A DNA ENCODING A GLYCINE TRANSPORTER AND USES THEREOF 未知
公开(公告)号：AU3071392A
公开(公告)日：1993-06-15
申请号：AU3071392
申请日：1992-11-12
申请人： SYNAPTIC PHARMACEUTICAL CORPORATION
发明人： KELLI SMITH , LAURENCE A BORDEN , THERESA BRANCHEK , PAUL R HARTIG , RICHARD L WEINSHANK
IPC分类号： C12N15/00 , A61K38/00 , C07K14/47
摘要： PCT No. PCT/US92/09662 Sec. 371 Date Nov. 10, 1994 Sec. 102(e) Date Nov. 10, 1994 PCT Filed Nov. 12, 1992 PCT Pub. No. WO93/10228 PCT Pub. Date May 27, 1993This invention provides isolated nucleic acid molecules encoding a mammalian glycine transporter, isolated nucleic acid molecules encoding a human glycine transporter, isolated proteins which are mammalian glycine transporter proteins, isolated proteins which are human glycine transporter proteins, vectors comprising isolated nucleic acid molecules encoding a mammalian or a human glycine transporter, mammalian cells comprising such vectors, antibodies directed to a mammalian glycine transporter, antibodies directed to a human glycine transporter, nucleic acid probes useful for detecting nucleic acid encoding mammalian glycine transporter, nucleic acid probes useful for detecting nucleic acid encoding human glycine transporter, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian glycine transporter, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human glycine transporter, pharmaceutical compounds related to mammalian glycine transporter, pharmaceutical compounds related to human glycine transporter and nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian or human glycine transporter. This invention also provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with mammalian glycine transporter. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with human glycine transporter.

2. 发明专利

TW200404779A 二芳基酮GALR3拮抗劑之方法和多晶型物 PROCESSES AND POLYMORPHS OF DIARYL-INDOLONE GALR3 ANTAGONISTS 审中-公开
简体标题：二芳基酮GALR3拮抗剂之方法和多晶型物 PROCESSES AND POLYMORPHS OF DIARYL-INDOLONE GALR3 ANTAGONISTS
公开(公告)号：TW200404779A
公开(公告)日：2004-04-01
申请号：TW092121466
申请日：2003-08-06
申请人：辛納波堤克製藥股份有限公司 SYNAPTIC PHARMACEUTICAL CORPORATION
发明人：約翰麥爾斯威徹爾 WETZEL, JOHN MYLES , 佛瑞伊約賓恩 JUBIAN, VREJ , 大衛T 約內伊堤斯 JONAITIS, DAVID T. , 克利斯堤昂M 雪爾茲 SCHERTZ, CHRISTINE M. , 麥可歐內爾 O'NEILL, MICHAEL
IPC分类号： C07D
CPC分类号： C07D209/40
摘要：本發明係關於化合物I〔1–苯基–3–〔〔3–(三氟甲基)苯基〕亞胺基〕–1H––2–酮〕的晶型及非晶型物，彼等的製備方法，含彼等之組成物及此等組成物之治療用途。本發明進一步關於製備化合物I之方法。
简体摘要：本发明系关于化合物I〔1–苯基–3–〔〔3–(三氟甲基)苯基〕亚胺基〕–1H––2–酮〕的晶型及非晶型物，彼等的制备方法，含彼等之组成物及此等组成物之治疗用途。本发明进一步关于制备化合物I之方法。

3. 发明专利

TW200410937A 治療抑鬱及/或焦慮症之3-亞胺基-2-酮化物 3-IMINO-2-INDOLONES FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY 审中-公开
简体标题：治疗抑郁及/或焦虑症之3-亚胺基-2-酮化物 3-IMINO-2-INDOLONES FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY
公开(公告)号：TW200410937A
公开(公告)日：2004-07-01
申请号：TW092121747
申请日：2003-08-07
申请人：辛那堤克製藥公司 SYNAPTIC PHARMACEUTICAL CORPORATION
发明人：麥可康凱爾 MICHAEL KONKEL , 約翰M 維塞爾 JOHN M. WETZEL , 傑米泰利斯曼 JAMIE TALISMAN
IPC分类号： C07D , A61K
CPC分类号： C07D401/04 , C07D209/40
摘要：本發明係有關對Ga1R3受體具有選擇拮抗性之酮衍生物。本發明提供一種醫藥組合物，其包含治療有效量之本發明化合物及醫藥可接受性載劑。本發明亦提供一種藉由結合治療有效量之本發明化合物及醫藥可接受性載劑所製得之醫藥組合物。本發明另提供一種製造醫藥組合物之方法，其包括結合治療有效量之本發明化合物及醫藥可接受性載劑。本發明亦提供一種治療患有抑鬱及／或焦慮症之個體之方法，其包括對該個體投予有效治療該個體抑鬱及／或焦慮症之量之本發明化合物。本發明亦提供一種於個體中治療抑鬱及／或焦慮症之方法，其包括對該個體投予包含醫藥可接受性載劑及治療有效量之Ga1R3受體拮抗劑之組合物。
简体摘要：本发明系有关对Ga1R3受体具有选择拮抗性之酮衍生物。本发明提供一种医药组合物，其包含治疗有效量之本发明化合物及医药可接受性载剂。本发明亦提供一种借由结合治疗有效量之本发明化合物及医药可接受性载剂所制得之医药组合物。本发明另提供一种制造医药组合物之方法，其包括结合治疗有效量之本发明化合物及医药可接受性载剂。本发明亦提供一种治疗患有抑郁及／或焦虑症之个体之方法，其包括对该个体投予有效治疗该个体抑郁及／或焦虑症之量之本发明化合物。本发明亦提供一种于个体中治疗抑郁及／或焦虑症之方法，其包括对该个体投予包含医药可接受性载剂及治疗有效量之Ga1R3受体拮抗剂之组合物。

4. 发明申请

WO2004050853A2 USES OF THE SNORF55 RECEPTOR 审中-公开
标题翻译： SNORF55受体的使用
公开(公告)号：WO2004050853A2
公开(公告)日：2004-06-17
申请号：PCT/US2003/038529
申请日：2003-12-03
申请人： SYNAPTIC PHARMACEUTICAL CORPORATION
发明人： ARTYMYSHYN, Roman , DELGADO, Lilliana , VAYSSE, Pierre, J.-J. , BERRADA, Karim , SMITH, Kelli, E. , GERALD, Christophe
IPC分类号： C12N
CPC分类号： C07K14/705
摘要： This invention provides methods of treating an abnormality that is linked to the activity of the mammalian SNORF55 receptor, as well as methods of determining binding of compounds to the mammalian SNORF55 receptor, methods of identifying agonists and antagonists of the SNORF55 receptor, and agonists and antagonists so identified.
摘要翻译：本发明提供了治疗与哺乳动物SNORF55受体的活性相关的异常的方法，以及确定化合物与哺乳动物SNORF55受体的结合的方法，识别SNORF55受体的激动剂和拮抗剂的方法以及激动剂和拮抗剂如此确定。

5. 发明申请

WO2004014855A1 PROCESSES AND POLYMORPHS OF DIARYL-INDOLONE GALR3 ANTAGONISTS 审中-公开
标题翻译： DIALL-INDOLONE GALR3拮抗剂的方法和多重性
公开(公告)号：WO2004014855A1
公开(公告)日：2004-02-19
申请号：PCT/US2003/025012
申请日：2003-08-07
申请人： SYNAPTIC PHARMACEUTICAL CORPORATION
发明人： JUBIAN, Vrej , WETZEL, John, M. , JONAITIS, David, T. , SCHERTZ, Christine, M. , O'NEILL, Michael
IPC分类号： C07D209/34
CPC分类号： C07D209/40
摘要： This invention relates to crystalline forms, as well as an amorphous form of Compound I [1-phenyl-3-[[3-(trifluoromethyl)phenyl]imino]-1H-indol-2-one], the processes for their preparation, compositions containing the same and the therapeutic use of such compositions. This invention further relates to a process for preparing Compound I.
摘要翻译：本发明涉及结晶形式，以及化合物I [1-苯基-3 - [[3-（三氟甲基）苯基]亚氨基] -1H-吲哚-2-酮的无定形形式，其制备方法，含有该组合物的组合物和这些组合物的治疗用途。本发明还涉及一种制备化合物I的方法。

6. 发明申请

WO2004014376A1 GAL3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF AFFECTIVE DISORDERS 审中-公开
标题翻译： GAL3受体拮抗剂治疗有害疾病
公开(公告)号：WO2004014376A1
公开(公告)日：2004-02-19
申请号：PCT/US2003/025133
申请日：2003-08-07
申请人： SYNAPTIC PHARMACEUTICAL CORPORATION
发明人： KONKEL, Michael , BLACKBURN, Thomas, P. , WETZEL, John, M.
IPC分类号： A61K31/44
CPC分类号： A61K31/425 , A61K31/40 , A61K31/405 , A61K31/42 , A61K31/44
摘要： This invention is directed to pyrimidine and indolone derivatives which are selective antagonists for the GAL3 receptor. This invention provides a method of treating a subject suffering from an affective disorder which comprises administering 'to the subject an amount of a compound of the invention effective to treat the subject's affective disorder. This invention also provides a method of treating an affective disorder in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GAL3 receptor antagonist. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of. a compound of the invention and a pharmaceutically acceptable carrier.
摘要翻译：本发明涉及作为GAL3受体的选择性拮抗剂的嘧啶和吲哚酮衍生物。本发明提供了治疗患有情感障碍的受试者的方法，其包括向受试者施用一定量的有效治疗受试者情感障碍的本发明化合物。本发明还提供了治疗受试者的情感障碍的方法，其包括向所述受试者施用包含药学上可接受的载体和治疗有效量的GAL3受体拮抗剂的组合物。本发明进一步提供了一种制备药物组合物的方法，包括将治疗有效量的本发明的化合物和药学上可接受的载体。

7. 发明申请

WO2003070916A2 DNA ENCODING SNORF44 RECEPTOR 审中-公开
标题翻译： DNA编码SNORF44受体
公开(公告)号：WO2003070916A2
公开(公告)日：2003-08-28
申请号：PCT/US2003/005230
申请日：2003-02-20
申请人： SYNAPTIC PHARMACEUTICAL CORPORATION
发明人： BONINI, James, A. , HUANG, Ling-Yan , WILSON, Amy, E.
IPC分类号： C12N
CPC分类号： C07K14/705 , A01K2217/075 , A61K38/00
摘要： This invention provides isolated nucleic acids encoding mammalian SNORF44 receptor, purified mammalian SNORF44 receptor, vectors comprising nucleic acid encoding mammalian SNORF44 receptor, cells comprising such vectors, antibodies directed to mammalian SNORF44 receptor, nucleic acid probes useful for detecting nucleic acid encoding mammalian SNORF44 receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian SNORF44 receptor, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian SNORF44 receptor, and methods of isolating mammalian SNORF44 receptor. This invention also provides methods of treating an abnormality that is linked to the activity of a mammalian SNORF44 receptor, as well as methods of determining binding of compounds to a mammalian SNORF44 receptor, methods of identifying agonists and antagonists of a SNORF44 receptor, and agonists and antagonists so identified.
摘要翻译：本发明提供编码哺乳动物SNORF44受体的分离的核酸，纯化的哺乳动物SNORF44受体，包含编码哺乳动物SNORF44受体的核酸，包含该载体的细胞，针对哺乳动物SNORF44受体的抗体，用于检测编码哺乳动物SNORF44受体的核酸的核酸探针的核酸探针，与编码哺乳动物SNORF44受体的核酸的独特序列互补的反义寡核苷酸，其表达编码正常或突变型哺乳动物SNORF44受体的DNA的转基因非人动物以及分离哺乳动物SNORF44受体的方法。本发明还提供了治疗与哺乳动物SNORF44受体的活性相关的异常的方法，以及确定化合物与哺乳动物SNORF44受体的结合的方法，鉴定SNORF44受体的激动剂和拮抗剂的方法，以及激动剂和如此确定的拮抗剂。

8. 发明申请

WO2003004027A1 SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS 审中-公开
标题翻译：作为选择性拮抗剂的替代苯胺哌嗪
公开(公告)号：WO2003004027A1
公开(公告)日：2003-01-16
申请号：PCT/US2002/021063
申请日：2002-07-03
申请人： SYNAPTIC PHARMACEUTICAL CORPORATION
发明人： MARZABADI, Mohammad R. , WETZEL, John , DELEON, John, E. , JIANG, Yu
IPC分类号： A61K31/445
CPC分类号： C07D231/12 , C07D211/26 , C07D211/28 , C07D211/90 , C07D233/56 , C07D249/08 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/06 , C07D405/12 , C07D409/06 , C07D409/10 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/06 , C07D417/10 , C07D471/04 , C07D495/04
摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.
摘要翻译：本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物与药学上可接受的载体组合。

9. 发明申请

WO1997046250A1 METHODS OF MODIFYING FEEDING BEHAVIOR, COMPOUNDS USEFUL IN SUCH METHODS, AND DNA ENCODING A HYPOTHALAMIC ATYPICAL NEUROPEPTIDE Y/PEPTIDE YY RECEPTOR (Y5) 审中-公开
标题翻译：改良饲料行为的方法，这种方法有用的化合物和编码高血压神经元神经营养素Y /肽受体（Y5）的DNA
公开(公告)号：WO1997046250A1
公开(公告)日：1997-12-11
申请号：PCT/US1997009504
申请日：1997-06-04
申请人： SYNAPTIC PHARMACEUTICAL CORPORATION , GERALD, Christophe, P., G. , WEINSHANK, Richard, L. , WALKER, Mary, W. , BRANCHEK, Theresa
发明人： SYNAPTIC PHARMACEUTICAL CORPORATION
IPC分类号： A61K38/02
CPC分类号： C07K14/70571 , A01K2217/05 , A61K38/00
摘要： The invention provides methods of modifying feeding behavior, including increasing or decreasing food consumption, e.g., in connection with treating obesity, bulimia or anorexia. These methods involve administration of compounds that are selective agonists or antagonists for the Y5 receptor. One such compound has structure (I). In addition, this invention provides an isolated nucleic acid molecule encoding a Y5 receptor, an isolated Y5 receptor protein, vectors comprising an isolated nucleic acid molecule encoding a Y5 receptor, cells comprising such vectors, antibodies directed to the Y5 receptor, nucleic acid probes useful for detecting nucleic acid encoding Y5 receptors, antisense aligonucleotides complementary to any unique sequences of a nucleic acid molecule which encodes a Y5 receptor, and nonhuman transgenic animals which express DNA encoding a normal or a mutant Y5 receptor.
摘要翻译：本发明提供了改变进食行为的方法，包括增加或减少食物消耗，例如与治疗肥胖，贪食或厌食有关的方法。这些方法包括施用作为Y5受体的选择性激动剂或拮抗剂的化合物。一种这样的化合物具有结构（I）。此外，本发明提供编码Y5受体，分离的Y5受体蛋白质的分离的核酸分子，包含编码Y5受体的分离的核酸分子的载体，包含该载体的细胞，针对Y5受体的抗体，有用的核酸探针用于检测编码Y5受体的核酸，与编码Y5受体的核酸分子的任何独特序列互补的反义寡核苷酸，以及表达编码正常或突变Y5受体的DNA的非人转基因动物。

10. 发明申请

WO1995021245A1 NUCLEIC ACID ENCODING NEUROPEPTIDE Y/PEPTIDE YY (Y2) RECEPTORS AND USES THEREOF 审中-公开
标题翻译：核酸编码神经元Y /肽YY（Y2）受体及其用途
公开(公告)号：WO1995021245A1
公开(公告)日：1995-08-10
申请号：PCT/US1995001469
申请日：1995-02-03
申请人： SYNAPTIC PHARMACEUTICAL CORPORATION , GERALD, Christophe , WALKER, Mary, W. , BRANCHEK, Theresa , WEINSHANK, Richard
发明人： SYNAPTIC PHARMACEUTICAL CORPORATION
IPC分类号： C12N05/10
CPC分类号： C07K14/70571 , A01K2217/05 , A61K38/00 , C12N2799/026
摘要： This invention provides isolated nucleic acid molecules encoding Y2 receptors, an isolated, purified Y2 receptor protein, vectors comprising isolated nucleic acid molecules encoding Y2 receptors, mammalian, insect, bacterial and yeast cells comprising such vectors, antibodies directed to the Y2 receptors, nucleic acid probes useful for detecting nucleic acid encoding Y2 receptors, antisense oligonucleotides complementary to unique sequences of a nucleic acid molecule which encodes a Y2 receptor, pharmaceutical compounds related to the Y2 receptors, and nonhuman transgenic animals which express nucleic acid encoding a normal or mutant Y2 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and methods of treatment involving Y2 receptors.
摘要翻译：本发明提供编码Y2受体的分离的核酸分子，分离的，纯化的Y2受体蛋白，包含编码Y2受体的分离的核酸分子，包含这种载体的哺乳动物，昆虫，细菌和酵母细胞的载体，针对Y2受体的抗体，核酸可用于检测编码Y2受体的核酸的探针，与编码Y2受体的核酸分子的唯一序列互补的反义寡核苷酸，与Y2受体相关的药物化合物和表达编码正常或突变的Y2受体的核酸的非人转基因动物。本发明还提供了确定配体结合，检测表达，药物筛选和涉及Y2受体的治疗方法的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式